Neurocrine Biosciences, Inc. (NBIX) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $150.44 (-4.31%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Josh Schimmer | Cantor Fitzgerald | $195.00 | +29.6% |
| Feb 17, 2026 | Danielle Brill | Truist Financial | $140.00 | -6.9% |
| Jan 5, 2026 | Ashwani Verma | UBS | $188.00 | +25.0% |
| Oct 29, 2025 | Danielle Brill | Truist Financial | $172.00 | +14.3% |
| Oct 29, 2025 | Paul Matteis | Stifel Nicolaus | $183.00 | +21.6% |
| Oct 29, 2025 | Ami Fadia | Needham | $184.00 | +22.3% |
| Oct 29, 2025 | Akash Tewari | Jefferies | $174.00 | +15.7% |
| Oct 9, 2025 | Ashwani Verma | UBS | $195.00 | +29.6% |
| Apr 22, 2025 | Andrew Fein | H.C. Wainwright | $168.00 | +11.7% |
| Jan 8, 2025 | Ashwani Verma | UBS | $162.00 | +7.7% |
| Oct 31, 2024 | Evan David Seigerman | BMO Capital | $121.00 | -19.6% |
| Oct 22, 2024 | Jay Olson | Oppenheimer | $192.00 | +27.6% |
| Oct 10, 2024 | Danielle Brill | Raymond James | $155.00 | +3.0% |
| Sep 13, 2024 | Evan David Seigerman | BMO Capital | $128.00 | -14.9% |
| Sep 9, 2024 | Carter Gould | Barclays | $160.00 | +6.4% |
| Aug 29, 2024 | Brian Abrahams | RBC Capital | $136.00 | -9.6% |
| Aug 29, 2024 | David Amsellem | Piper Sandler | $159.00 | +5.7% |
| Jul 12, 2024 | Jeffrey Hung | Morgan Stanley | $170.00 | +13.0% |
| Jun 6, 2024 | Brian Abrahams | RBC Capital | $141.00 | -6.3% |
| May 28, 2024 | Ashwani Verma | UBS | $193.00 | +28.3% |
Top Analysts Covering NBIX
NBIX vs Sector & Market
| Metric | NBIX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.16 | 2.25 | 2.42 |
| Analyst Count | 37 | 8 | 18 |
| Target Upside | +29.7% | +16187.2% | +19.5% |
| P/E Ratio | 32.28 | 3.76 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $882M | $905M | $943M | 10 |
| 2026-12-31 | $3.27B | $3.47B | $3.60B | 12 |
| 2027-03-31 | $904M | $927M | $955M | 11 |
| 2027-06-30 | $991M | $1.02B | $1.05B | 7 |
| 2027-09-30 | $1.06B | $1.08B | $1.11B | 8 |
| 2027-12-31 | $1.06B | $1.09B | $1.12B | 7 |
| 2028-03-31 | $1.45B | $1.49B | $1.53B | 6 |
| 2028-06-30 | $1.50B | $1.54B | $1.58B | 6 |
| 2028-09-30 | $1.54B | $1.57B | $1.62B | 11 |
| 2028-12-31 | $1.57B | $1.61B | $1.65B | 6 |
| 2029-12-31 | $4.41B | $4.65B | $4.86B | 11 |
| 2030-12-31 | $4.77B | $5.03B | $5.26B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.67 | $1.73 | $1.82 | 3 |
| 2026-12-31 | $5.35 | $6.12 | $6.99 | 8 |
| 2027-03-31 | $1.40 | $1.44 | $1.50 | 3 |
| 2027-06-30 | $1.65 | $1.70 | $1.77 | 5 |
| 2027-09-30 | $1.91 | $1.98 | $2.05 | 3 |
| 2027-12-31 | $1.89 | $1.95 | $2.02 | 6 |
| 2028-03-31 | $5.03 | $5.20 | $5.40 | 4 |
| 2028-06-30 | $5.41 | $5.59 | $5.81 | 6 |
| 2028-09-30 | $5.56 | $5.74 | $5.97 | 4 |
| 2028-12-31 | $5.74 | $5.93 | $6.16 | 7 |
| 2029-12-31 | $10.74 | $11.50 | $12.18 | 4 |
| 2030-12-31 | $12.80 | $13.70 | $14.51 | 4 |
Frequently Asked Questions
What is the analyst consensus for NBIX?
The consensus among 37 analysts covering Neurocrine Biosciences, Inc. (NBIX) is Buy with an average price target of $188.62.
What is the highest price target for NBIX?
The highest price target for NBIX is $200.00, set by Jay Olson at Oppenheimer on 2024-03-12.
What is the lowest price target for NBIX?
The lowest price target for NBIX is $100.00, set by Carter Gould at Barclays on 2022-01-20.
How many analysts cover NBIX?
37 analysts have issued ratings for Neurocrine Biosciences, Inc. in the past 12 months.
Is NBIX a buy or sell right now?
Based on 37 analyst ratings, NBIX has a consensus rating of Buy (2.16/5) with a +29.7% upside to the consensus target of $188.62.
What are the earnings estimates for NBIX?
Analysts estimate NBIX will report EPS of $1.73 for the period ending 2026-09-30, with revenue estimated at $905M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.